Jesús San Miguel, MD, PhD, from the University of Navarra, Navarra, Spain gives an overview of immunomodulatory drugs (IMiDs) thalidomide, lenalidomide and pomalidomide for multiple myeloma (MM). According to Prof San Miguel, these drugs have reinforced the value of the immune system. The tumor cells use various mechanisms to evade immune system control, such as the PD-1/PDL-1 pathway. The monoclonal antibody pembrolizumab can release this particular break on the immune system. Prof San Miguel explains how preliminary data shows, that at the time of minimal residual disease (MRD) and relapse, the PD-1 is expressed on the T-cells and PDL-1 on the tumor cells and explains the synergy between various drug combinations.
Recorded at the Myeloma 2016 meeting held in Boston, MA.